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Background/aim: Levodopa-carbidopa intestinal gel (LCIG) is an effective treatment modality in the management of advanced
Parkinson’s disease (PD) despite frequent adverse events and different rates of dropouts. Efficacy and safety data regarding Turkish
patients on LCIG are limited. This study aims to report in detail the efficacy and adverse effect profile of LCIG among advanced PD
patients from a Turkish center for movement disorders.
Materials and methods: Twenty-two patients (50% male) who started receiving LCIG between December 2014 and March 2020 were
recruited. The efficacy of LCIG was assessed with the Unified Parkinson’s Disease Rating Scale (UPDRS III), Clinical Global İmprovement
(CGI) scale, and Quality of Life scale (PDQ8). Improvements in gait disorders and nonmotor features were also questioned. Adverse
events (AE) were collated into 3 topics: related to percutaneous endoscopic gastrojejunostomy (PEG-J), device-related, and LCIG
infusion-related.
Results: Mean age and pre-LCIG disease duration were 66.7 (8.8) and 13.3 (8.0) years respectively. UPDRS III scores and H-Y scale
assessments significantly improved. Better quality of life scores, clinical global improvements, and improvements in dysarthria,
dysphagia, and gait were observed. None of our patients dropped out or died during a mean 17.5-month (12.3) period. Overall 20
(90.9%) patients experienced at least one AE.
Twelve patients had PEG-J–related complications; three had acute abdomen. Eight (36.4%) patients had device-associated problems.
Half of the patients required at least one additional endoscopic procedure and 7 had a device replaced. Mean body weight decreased
from 69.5 to 62.5 kg and seven patients had newly onset PNP at a follow-up electromyography. Dyskinesia related to LCIG infusion was
observed in 5 (22.7%) patients. There was no significant increase in hallucination among patients.
Conclusion: LCIG is an efficient treatment modality in the management of Turkish patients with advanced Parkinson’s disease.
Although most of the patients had at least one AE, none of them dropped out. Patient selection, patient compliance, and collaborative
management are important steps affecting the success of modality.
Key words: Advanced Parkinson’s disease, LCIG, Duodopa, PEG-J, dyskinesia, PDQ

1. Introduction
With a combination of oral Levodopa (L-dopa) and
dopamine agonists, cardinal symptoms of Parkinson’s
disease (PD) are effectively treated. However, long-term
oral L-dopa treatment results are hampered by motor
complications such as dyskinesias and fluctuations [1].
Motor and nonmotor complications are often related
to fluctuating levels of serum levodopa secondary to
delayed gastric emptying [2]. In 2005, it was shown
that a levodopa-carbidopa intestinal gel (LCIG) infusion
effectively reduced daily off time and motor fluctuations
in advanced PD [3]. The results of GLORIA registry-

recruited 375 patients across Europe provide evidence for
the long-term effectiveness in reducing motor fluctuations
and dyskinesias during routine clinical care [4]. Besides
efficacy, LCIG modality has adverse events related to PEG
procedure, infusion devices, or LCIG treatment [5]. These
adverse events, including weight loss and polyneuropathy
(PNP), are significant concerns and could be a potential
cause of withdrawal in patients on LCIG [5,6]. A
collaborative approach is required to manage these diverse
complications.
Even though this modality has been approved for
clinical use worldwide for almost 15 years, data regarding
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efficacy and safety of LCIG treatment of Turkish PD
patients are limited. This study aims to report the efficacy
and adverse effect profile of LCIG in detail among advanced
PD patients from a Turkish center for movement disorder.
2. Materials and methods
2.1. Patients
Twenty-two patients (50% male) were recruited who
started receiving long-term treatment of LCIG at our
Movement Disorders Clinic between December 2014
and March 2020. The study was approved by the Chief
Physician of Ankara City Hospital. All patients signed
a consent form before undergoing a percutaneous
endoscopic gastrojejunostomy (PEG-J) procedure and for
the collection and reporting of data.
Criteria required for being a candidate for LCIG are:
· Age > 30 years,
· Diagnosis of PD according to United Kingdom PD
Society Brain Bank criteria [7],
· Levodopa responsiveness assessed using the Levodopa
Challenge test (>40% recovery of UPDRS III scores),
· Significant motor fluctuations and dyskinesias despite
optimized PD therapy, as judged by the investigator,
· Recognizable off and on states, with a minimum 3 h
off time per day at baseline, and the ability (by patient or
caregiver) to competently maintain a standard PD diary.
Major exclusion criteria include unclear PD diagnosis;
a Mini-Mental State Examination score of <24; current
primary psychiatric diagnosis of acute psychotic disorder,
bipolar disorder, or major depressive disorder; or a history
or presence of any condition that might interfere with
absorption, distribution, metabolism, or excretion of the
study drug or any contraindication to the placement of an
intrajejunal PEG-J tube.
2.2. Mode of administration and dosing of LCIG
LCIG contains 20 mg/mL levodopa and 5 mg/mL
carbidopa and is supplied in cassettes containing 100 mL
of gel solution delivered directly into the small intestine via
a modified portable CADD‐Legacy® PCA (Smiths Medical,
St. Paul, MN, USA) infusion pump worn by the patient.
The most common surgical procedure is the
implantation of a permanent catheter in the jejunum using
a percutaneous endoscopic gastrojejunostomy (PEG-J)
procedure with an outer transabdominal tube and an
inner intestinal tube.
During the first day of hospitalization, we calculated
the dose of LCIG to administer from the oral dose of
levodopa, and dopamine agonists by using the levodopa
equivalent daily dose (LEDD).
Individually optimized dosing of LCIG was delivered
over a 16-h period, administered as a morning bolus
followed by continuous infusion, and if needed, intermittent
extra doses (patient-initiated based on symptom

experience). None of our patients was administered
24-h period of LCIG; instead, extended released form of
levodopa-carbidopa was used for nocturnal off symptoms.
2.3. Clinical and safety evaluation
Clinical data, neurophysiological assessments, and
laboratory tests were collected at baseline (before LCIG
implantation) and during follow-up.
During a semistructured interview with the patient
and the caregiver, we assessed the efficacy of motor
features using UPDRS (part motor-III performed in the
on state); improvement in dysphagia, dysarthria, gait
disorders (rated on a 3-point scale: improvement, no
change, worsening); PD quality of life (QoL) 8 and 9;
and Clinical Global Improvement (rated on a 5-point
scale: great improvement, moderate improvement, slight
improvement, no change, worsening) after LCIG [8].
Information on motor symptoms (wearing off, h/day spent
in off), patient function/satisfaction, and the timing (on,
off, or transitional) of dyskinesia were collected using home
diaries. The presence of nonmotor symptoms (depression,
hallucinations, insomnia, REM sleep disorders,
incontinence, constipation, orthostatic hypotension) was
questioned before and after LCIG treatment.
Patients were evaluated not only in terms of PD
features but also body weight and peripheral neuropathy
1, 3, and 6 months after the procedure and then, every 3
months. Baseline and follow-up electromyography was
performed. All patients recruited for LCIG infusion had
serum vitamin B12 and folate assessments (in case of
B12 level <150 mg/dLàintramuscular B12 replacement,
folate level <5 à 5 mg of oral folate 2 days per week was
recommended). All adverse events occurring during LCIG
treatment were collected and categorized as I: PEG-J–
related; II: device-related; III: LCIG-infusion-related [8].
Treatments for PD, antidepressants, and antipsychotics,
before and after LCIG were recorded. The total daily dose
of infusion and the involvement of a caregiver for setting
up and shutting down the device were investigated.
2.4. Statistical analysis
Statistical analysis was performed with SPSS Version 21.0.
Results were expressed as mean and standard deviation
for continuous variables and as absolute numbers and/or
relative frequencies (%) for categorical variables. To find out
any difference at baseline and follow-up, a paired samples
t-test was used for numeric variables and a McNemar test
was used for categorical variables. A P-value of <0.05 was
considered statistically significant.
3. Results
Mean age and pre-LCIG disease duration were 66.7 (8.8)
and 13.3 (8.0) years, respectively. At baseline, the patient
UPDRS part III mean was 38.3 (7.18) and they had a mean
off time of 9.1 (2.7) h/day. The demographic and clinical
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features of patients are shown in Table 1. All of the patients
were taking at least 2 PD medications before LCIG (Table
2).
3.1. Clinical evaluation
All of the patients have been using LCIG after a mean
17.5-month (12.3) period. There were significant
improvements in UPDRS III scores and H-Y scales.
Furthermore, a better quality of life score, clinical
global improvements, and improvements in dysarthria,
dysphagia, and gait have been detected (Table 2). Needing
help from a caregiver decreased to half frequency.
All of the patients had an increased total daily dose and
post-LEDD was increased compared to baseline (Table
2, P = 0.004). LCIG treatment decreased the frequency
of nonmotor symptoms such as sleep disorders and
depression along with PDQ-9 scores. There is no change
in using concomitant antidepressants and antipsychotics.
3.2. Safety
Although 20 (90.9%) patients experienced at least one AE
(Table 3), none of the patients dropped out or died during
the study period.
Twelve patients had PEG-J–related complications; 3 of
them had acute abdomen. One patient was hospitalized in
the intensive care unit due to suspected ileus and excessive
vomiting resulting in aspiration pneumonia.
Eight (36.4%) patients had device-associated problems.
Half of the patients required at least one additional
endoscopic procedure and 7 had a device replaced.
LCIG infusion therapy-related adverse events were
reported in 13 patients (59.1%). Dyskinesia related to LCIG
infusion was observed in 5 (22.7%) patients. There was no
significant increase in hallucination among patients.
Weight loss was reported in 8 patients. Mean body
weight decreased from 69.5 (15.1) kg to 62.5 (15.2) kg (P <
0.001) corresponding to a weight change greater than 10 kg
in 6 (27.3%); patients ranging from 6 to 10 kg in 5 (22.7%)
patients; and from 2 to 5 kg in 7 patients (31.8%). No
significant weight changes were observed in the remaining
4 patients. Nutritional support has been recommended in
case of weight loss >5 kg (2 of 5 patients, 6–10 kg; 3 of 6
patients, >10 kg).
Eleven patients with no PNP in the baseline EMG did
not experience PNP afterward. While 3 patients had PNP
at baseline, 7 patients had newly onset PNP at follow-up.
There was no significant difference in terms of baseline and
follow up vitamin B12 levels (345.3 ng/mL (204) vs. 618
ng/mL (766), P = 0.096) whereas homocysteine levels were
increased (15.7 (5.3) vs. 28.8 (8.6) <0.001, respectively).
4. Discussion
LCIG has been used for advanced PD disease worldwide
for approximately 2 decades. Since it has a diverse
adverse effect profile, collaborative management of these
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Table 1. Baseline demographic and clinical features of patients.
Characteristics

Value

Male sex

11 (50%)

Age, years

66.7 (8.8)

Comorbid disease
· Diabetes mellitus
· Malignancy
· Vitamin B12 deficiency

· 2 (9.1%)
· 1 (4.6%)
·0

Age at PD diagnosis, years

52.0 (12.9)

Pre-LCIG PD duration, years

13.3 (8.0)

LCIG duration, months
· Mean
· Median

· 17.5 (12.3)
· 14.5 (6–60)

Hoehn & Yahr scale

3.09 (0.7)

UPDRS Part III (motor examination)

38.3 (7.18)

MMS, total score

26.7 (2.4)

Values are labeled as mean (SD), median (minimummaximum) or n (%)

patients is essential. This is the first study reporting
efficacy and adverse effects of patients on LCIG from a
Turkish center for movement disorders. We had observed
significant improvements in clinical parameters. In a
mean 17.5-month follow-up, 90% of patients had AE. A
collaborative team is useful to handle these sometimesproblematic adverse effects. As a result, all of our patients
have been still using LCIG.
Concerning the efficacy outcomes, our study confirms
the well-known efficacy of LCIG treatment on motor
and nonmotor fluctuations in PD with a good degree
of satisfaction of both patients and physicians [4,5,9]. A
significant reduction in the time spent in the off condition
was observed. Most patients reported a great or moderate
improvement in their quality of life and clinical global
improvements in parallel to previous studies [8,9]. The
frequency of caregiver requirement for PD treatment
decreased to half of the baseline.
Nonmotor features such as depression and sleep
disorders also improved. Excessive daytime sleepiness
is a well-known side effect of Dopa agonists. Cessation
of these drugs after LCIG might have a beneficial role in
improving sleep quality. PDQ-9 scores decreased without
any change in antidepressant usage. Levodopa-based
continuous dopaminergic stimulation is beneficial for
NMS and health-related quality of life in PD [10].
Overall, the daily dose of levodopa was increased and
pharmacologically therapy was greatly simplified. This
increase is common in clinical practice when switching
from oral PD medications to LCIG [4]. The continuous
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Table 2. Efficacy assessments and pre-/post-LCIG treatment of patients.
Baseline parameters

Post-LCIG

P

UPDRS Part III

38.3 ± 7.18

13.09 (5.05)

0.014

Hoehn & Yahr During On

3.09 (0.7)

1.77 (0.59)

<0.001

Off time, h/day

9.1 (2.7)

1.09 (0.86)

0.022

PD-Q8

22 (6.98)

9.4 (6.5)

<0.001

Clinical Global Improvement, %
· Great
· Moderate
· Slight
· No change
· Worsening

NA

Dysarthria, %
· Improvement
· No change
· Worsening

NA

Gait, %
· Improvement
· No change
· Worsening

NA

Dysphagia, %
· Improvement
· No change
· Worsening

NA

Help from caregiver, %

77.1

36.1

Nonmotor symptoms, %
· depression
· hallucinations
· insomnia
· RSD
· incontinence
· constipation
· orthostatic hypotension

· 68.2
· 40.9
· 31.2
· 27.3
· 27.3
· 45.5
· 9.1

· 18.2
· 45.5
·0
·0
·0
· 36.4
·0

PD-Q9

15.3 (7.1)

7.45 (5.09)

<0.001

LEDD, mg/day

942 ± 377

1121 (282)

0.004

PD medications, %
· Dopamine agonists
· COMT inhibitors
· MAO-B inhibitors
· Amantadine
· Evening L-dopa

· 72.7
· 68.2
· 59.1
· 81.8
· 95.5

· 18.2
·0
· 9.0
· 90.9
· 100

· <0.001
· <0.001
· 0.001
· 0.5
· 0.5

Antidepressants usage, %

40.9

36.3

>0.05

Antipsychotics usage, %

59.9

59.9

> 0.05

· 50
· 45.5
· 4.5
·0
·0
· 45.5
· 45.5
· 9.1
· 72.7
· 13.6
· 13.6
· 9.1
· 72.7
· 18.2
0.004
· 0.001
· 1.0
· <0.001
· <0.001
· <0.001
· 0.5
· 0.3

Values are labeled as mean (SD) or %, NA: not administrated, RSD: REM sleep disorder.

nature of levodopa delivery with LCIG often allows
for an increase in LEDD for optimal motor symptom
control while limiting many of the undesirable side effects
associated with high oral levodopa dose. In our study,
dyskinesia related to LCIG infusion was reported in a

small group of patients. No significant increase was found
among patients in terms of hallucination.
A relatively high number of AE occurred during
the follow-up including technical problems with the
infusion device and problems related to jejunostomy.
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Table 3. Adverse events.
PEG-J–related
· Abdominal pain
· Leakage
· Stoma infection
· Abscess
· Acute abdomen

12 (54.5%)
· 12 (54.5%)
· 7 (31.8%)
· 10 (45.5%)
· 2 (9.1%)
· 3 (13.6%)

Device-related
· Dislocation
· Occlusion
· Reimplantation

8 (36.4%)
· 3 (13.6%)
· 3 (13.6%)
· 7 (31.8%)

LCIG-infusion-related
· Weight loss
· Dyskinesia
· Hallucination
· Disorientation
· Newly-onset PNP

13 (59.1%)
· 8 (36.4%)
· 5 (22.7%)
· 10 (45.5%)
· 1 (4.5%)
· 7 (31.8%)

Infections and inflammation comprised the majority of
procedure-related events; 3 patients had acute abdomen
and 1 required surgical intervention. A patient with ileus
resulting in aspiration pneumonia was followed up at the
intensive care unit at the 12th month of LCIG. No patients
died during follow-up. The possibility of serious events
highlights the importance of a multidisciplinary approach
to LCIG treatment since the correct management of
LCIG-related problems may demand gastroenterological,
radiological, and surgical expertise.
Weight loss (WL) is a frequent but underrecognized
complication of LCIG infusion. Nutritional status
monitoring is essential during treatment. According to this
monitorization, nutritional support was recommended in
case of severe weight loss to our patients. However, there
was a mean 7 kg loss. The complex association between
weight loss, poor nutritional status, motor complications,
and PD progression, however, remains unclear.
More than one-third of PD patients in treatment
with L-dopa may develop PNP, with a significantly
higher prevalence of acute and subacute forms in those
receiving LCIG [11,12]. Rispoli et al. showed 19% with
new-onset PNP in 30 LCIG patients during a 42-month
follow-up [13]. In our series, 3 patients had pre-LCIG PNP
none of them worsened. On the other hand, 7 patients had
newly onset mild-moderate PNP; none developed acutesubacute PNP. The presence of new PNP did not lead to
discontinuation of therapy as reported in other studies.
Vitamin B12 replacement was not able to prevent new
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cases of PNP. No patients had low vitamin B12 levels but
there was a significant increase in homocysteine levels after
follow-up. Pathogenic mechanisms are possibly related to a
complex interplay between peripheral neurodegenerative
processes and L-dopa neurotoxic metabolites [12,14].
Periodic screening of these parameters together with
neurophysiological assessment for neuropathy may be
advisable to PD patients who are receiving LCIG.
In previous studies, a reasonable percent of patients
on LCIG treatment had dropouts changing between
18.6% and 38.8% around the 2-year follow-up [5,6,11].
LCIG interruption could be due to AE, lack of efficacy,
and rejection of the device. Zero dropped out of the
study, which could be a result of several factors. Firstly,
we used the levodopa challenge test in the course of
patient selection for LCIG. It is rational to better define
the profile of a good responder of levodopa. Secondly, in
each candidate case, we had a long-duration pre-LCIG
meeting with the patient and caregiver about the course
of modality. Proper informing about the device and how
to use it is essential. Thirdly, we discussed every AE and
how to manage them in our multidisciplinary meeting.
Collaboration is essential to handle these adverse events.
The limitation of this study is a cohort with a small
number of patients. Assessment of efficacy and AEs
could be enriched with additional usage of UPDRS-IV
and objective assessment of dyskinesia and hallucination.
However, we presented a comprehensive assessment of
efficacy and adverse events. Since this is a prospective
cohort, we hope to present it with larger numbers.
In conclusion, LCIG is an efficient treatment modality
in the management of Turkish advanced Parkinson’s
disease patients. Patient selection, collaboration, and
patient compliance are important steps affecting the
success of modality including the dropout number, which
is zero for our cohort.
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